Q4 2020 Amneal Pharmaceuticals Inc Earnings Call
[music].
Good morning, and welcome to the Amnio Pharmaceuticals fourth quarter and full year 'twenty 'twenty earnings conference call, all participants will be in listen only mode.
You need assistance. Please signal a conference specialist by pressing Star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions to ask a question. You May Press Star then one on your telephone keypad to withdraw your question. Please press Star then two please.
Note. This event is being recorded I would now like to turn the conference over to touch on what's Gonna Dorris Executive Vice President and Chief Financial Officer. Please go ahead.
Good morning, and thank you for joining <unk> fourth quarter and full year 2020 earnings call.
Earlier. This morning, we issued a press release reported financial results.
The press release as well as the slides that will be presented on this call on available on our website on www Dot <unk> Dot com, we are conducting a live webcast on this call a replay of which will also be available on our website. After its conclusion.
Please note that today's call is copyrighted material a bit on the island.
Cannot be rebroadcast without the company's six price great income.
<unk>.
I'd like to remind you that statements made during this call, stating management's outlook or predictions for future periods are forward looking statements. These statements are based solely on information that is now available to us.
We encourage you to review the section entitled cautionary statements on forward looking statements in our press release and presentation, which applies to this call.
Our future performance may differ.
Numerous factors many of which are.
On the basis on our most recent annual report on form 10-K, and our revised and updated on our quarterly reports on form 10-Q.
And current reports on form 8-K, which you can also find on our website or on the SEC's website at SEC Gov.
Well also discuss certain non-GAAP measures you will find important information I don't know use of these measures and a reconciliation to GAAP GAAP in our earnings release.
In the appendix of today's presentation, you can find U S. GAAP financial measures metrics that correspond to some of our U S. non-GAAP.
GAAP measures, we reference throughout the presentation.
On this call. This morning are <unk> continue to propel our co Ceos and people here and Josef <unk>, our chief commercial officer sort of on generics and specialty segments.
As well as statements on our general counsel and corporate Secretary.
I will now turn the call over to Sean.
Thank you good morning, and thank you for joining us in the review of revenues fourth quarter and full year 2020 results.
We are pleased with our strong finish in the fourth quarter with net revenue of $510 million up 28% versus prior year, and adjusted EBITDA of $107 million up 33% and adjusted EPS of <unk> 14 cents up substantially versus <unk>.
Yes.
Our strong and consistent financial performance over the course of 2020 matched or exceeded our guidance metrics and reflects the successful execution of our strategy. Despite the impact of COVID-19 pandemic. This performance could not have been possible.
Without their resiliency and dedication Alcoa global team.
Whose commitment to meeting the needs of the renovation has enabled us to drive continued growth throughout the public health crisis.
And we are just getting started.
I'm very optimistic about on a glitch in the DS in the months and years ahead as we enter.
2021, with solid momentum and a clear vision, what I needed to point out.
It's been a year and a half is she'll do on I returned as a co Ceos plan to reinvigorate our genetics business.
And then it was specialty franchise diversify our distribution channels and enhance operational execution.
Since then we have made significant progress to strategically position on meal, both operationally and financially.
The next phase of growth.
I'd now like to take few minutes to recap of whatever new share over the last year.
Outline our longer term revenue to playing those strategy.
Let me start with other generics business, which delivered approximately $1 3 billion in net revenues in 2020 in the past 18 months, we have significantly strengthened in June.
Generics portfolio and we are confident in our ability to drive long term sustainable growth for three main reasons.
We will continue to leverage on a broad commercial presence and growing portfolio of approximately 250 commercial products to increase on our market share.
Our success in 2020 was due to strong performance in both on base business and new product launches, which are <unk>.
Pleasingly complex and have higher barriers to entry recent Northwood noteworthy launches include other genetic lesions on.
The wedding kind of afraid to <unk> ex <unk> batch on.
The way I would a patch for lake city et cetera, as we look forward to 2021 and beyond we remain extremely excited about other pipeline.
Second this is an innovation driven business and we have already taken many steps to transition out on India in June to focus on complex bartolomei, such as injectable.
Upon mix and this transition has been the year's long effort and it has only recently begun to Dubai crude in our commercial portfolio.
In other way the investment we have already made across R&D and manufacturing will generate substantial growth over the next few years and we have no intention of slowing down our talented R&D employees throughout the U S Ireland, India make this possible and I would have expected.
The acquisition of cash use specialty pharma will further boost this already dynamic team Shinbu will touch on R&D momentarily.
Third we are actively working on growing dealer business in ex U S. Geographies as you know two days our sales are generated almost exclusively in the United States volume, we have a fantastic portfolio of accrued andas and significant pipeline behind that we have begun the process.
Since of leveraging these assets to commercialized genetics internationally through partnerships. China. For example is a massive market and we are acutely aware of the opportunity it represents to.
Through our partnership with <unk> pharma, we have already filed for products with the Chinese FDA and plan to pilot to 10 more in 2021.
We expect to have China business to be commercial in 2023, and this is just one of the multiple strategies to out license other genetics and new geographies more to come here over the coming quarters, Let me now turn it over.
Turning to our specialty business, which delivered approximately 356 million in net revenue in 2020, we are pleased with the prescription growth of our key promoted brands. So back to the annuity story. We believe these brands address substantial unmet needs and we continue to invest in ensuring that.
Long term potential.
At the same time, we are strategically building a deep R&D pipeline projects focused on leveraging our commercial expertise.
<unk> infrastructure in neurology and endocrinology in the short term we remain very excited about bogard, two CNS programs IPX towards free and key $1 seven IP extraordinary is on track for phase III topline read out in the third quarter of this year and Q1 two seven.
And is advancing well into clinic.
And they announced spending acquisition on Kashi specialty pharma would provide us with two additional specialty programs day one.
One four and Q1, two eight which doubles our pipeline core programs, which launch potential in the next five years.
While it's too early to project on newer revenues or cash.
As shown on investing in new specialty programs is and you'll be yourselves of at least $100 million.
Finally, we feel very good about our improved financial flexibility as a competitive edge.
The end of 2019 to come on these net debt to adjusted EBITDA was seven three ex.
I'm pleased to report that we finished 2000 25.3 ex net debt to adjusted EBITDA, a two turn reduction over 12 months or improved financial flexibility enables us to continue to look for accretive M&A transactions, which will leverage our commercial expertise in Peru.
Our growth profile and help us to build on our specialty franchise.
Daily monitoring of opportunities to make this segment a larger part of <unk> business in the coming years, and we are evaluating multiple structures, including both partnerships and M&A.
Let me now move to other distribution business, which closed 2020 with 294 million in net revenue. We are pleased how the business performed its first year as an independent subsidiary to your volume despite headwinds from COVID-19, looking ahead to 2021, our primary focus remains.
Expanding on market share within MKS, we a D O D chose and expanding on unit dose business.
Over the next five years, we expect a large addressable market on branded products growing genetics, and we believe <unk> is well positioned to win like.
Let me briefly touch on on what equity to.
To support domestic Palmer sugar production in this country.
As we know Covid has highlighted the importance of local manufacturing and good brightness and strengthening the supply chain other essential medicines in the United States other operational expertise and quality record uniquely position us to be part of an expanded domestic drug manufacturing strategy to further grow the se.
Earnings while.
On the Whiting Americans assurance that debt essential medicines will be day, when they need them.
With that let me turn the call over to Chengdu, who will provide more color around our growth strategy.
Good morning, everyone bankers your dogs too.
Well my brother sentiment, let me first acknowledge our talented and dedicated employees across every site and function together they are working tirelessly to deliver smart business.
Many of these strategies and our relentless commitment to employee health and wellness.
Especially grateful part of our frontline teams, whose determination and creativity and shorts and ongoing supply of quality Marty's thing to our customers on patients together our team delivered strong results and progress being 'twenty 'twenty, we continue to revitalize our generics R&D.
And commercial business growing our specialty franchise and pipeline and improved margins and cash flow as Doug noted these weighted the strategy used to be stacked up on our return to the company in late 2019, and our execution has positioned us for continued growth and success.
<unk> on day, one and beyond our current.
It meant to support manufacturing and quality standards remain on the way waiting or manufacturing facilities are operating EBITDA.
How are you capacity, which is improving our gross margins.
We also continue to uphold the highest standard saw good manufacturing practices and integrity, which have been hallmarks of our company since its founding 19 years ago. Our global R&D team is already firing a foundation for sustainable long term growth or generic pipeline now includes nine different.
Drug delivery platforms.
Uniquely position to develop and commercialize complex dosage forms in house antibody integrated supply chain helps us bring complex products to market faster more reliably and more cost efficiently. Let me spend a few minutes on our progress with generics R&D.
Our generics business continues to improve across our top and bottom lines in late 2019, we promise to launch at least 15 high value complex generics within two years, we are on track to achieve this goal by August 2021.
And we will not stop there. We also expect launch at least six to stay on high value products on a yearly basis going forward.
On the 20 2029, new Anda filings and we expect to file at least Turkey products in 'twenty 'twenty, one of which 80 per cent will be non oral solid dosage forms as you can see there's good momentum in our core business and the Fantastic example, on that is that all of our genetics.
You ran on Gulf of Ortho, EVRA patch, which we announced this morning and will compete with my legs Julien the only other dogfight would I agree relative on the market, we will have a C. G T.
Excuse me would be fought ex month on this product and it is part of that guidance off of our portfolio transformation to complex products and this is only one upside what on strong launches since the start of 'twenty 'twenty, one and just last two months. We have also launched generic day digger and three lower sand proppant United Truvada.
We are focused on generating meaningful growth in our sterile products over the next 18 to 24 months, which will better meet the demands of our rapidly growing institutional and complex generics retail business.
Or what are the next five years, we expect to launch at least 50 style products, including but not limited to microspheres like was almost peptides auto injectors ophthalmic and artists antibody inhalation platform continues to make great strides we have one inhalation product currently flying with several hundred.
Look man and we are targeting approximately three launches in these ADR grew 2025 years as we continue developing and commercializing complex genetics will be sharply ex Florida ex U S opportunities for these products, which can be very significant why a partnership model.
On Biosimilar, we believe this will be a meaningful segment of growth for M need overtime why do you guys still in the early innings to be believed the biosimilar market will behave more like the complex generics market over time.
Moving to and the strength of high quality manufacturing and nimble execution. We are actively evaluating lower risk partnership models debt utilized scientific innovation and cost efficient development and commercialization strategies. We also remain focused on being first or second to market.
Across all therapeutic areas in the second wave of Biosimilars I would like to take the opportunity now to walk through the growth opportunities that the cash shoe specialty pharma deal, but he breaks that's starting with genetics Kashi has been one of our most successful R&D partner acquiring TSB will provide.
With a specialized and expedia on steam on 75 scientist and a pipeline of potential first to file opportunities in categories, such as a drug device combination hot melt extrusion and other mortified release forms the deal will also boost our operations network by adding on.
R&D and complex manufacturing center of excellence in Bridgewater, New Jersey.
Moving to specialty we are excited about cash use proprietary technology in a drug delivery, let's start with Grande, which is the technology behind cable on one four and gateway to stay at one Grand day is the gastric retentive drug delivery technology suitable for up to 20 per cent of compound.
There are typically absorbed in the upper Gi tract through these technology to through these technology retention in the stomach last 18 to 24 hours compared to eight to 10 hours of most commercialized drugs with Simi liabilities the poll.
Tangela application for this technology, which has simply been tested in over 300 human subjects is substantial Q1 'twenty stay when it is expected to allow for once daily dosing of viral stigma and for myasthenia gravis and gave on one four is expected to provide 24 hour sustained.
Believe it or your teeth free port hypo titled ease the bolthouse significant commercial opportunities, but decided just that people dice book.
He had 128, which is <unk> extended release dry ex the final candidate for Si Lauria allows for long acting controlled release of drug.
These are all other products that we have disclosed so far gosh. You also had the effect of early stage products that are in current incredibly promising for instance, the carano Tech platform is on advanced automotive oral delivery technology that provides timed customized and allstate aisle drug that he needs to.
Match the timing of this these symptoms bearish on of these technologies will create a capable and sustainable organic growth engine for <unk> specialty. We also expect to increase the shadow for internal R&D budget directed to branded product development in a measured and responsible way both gave on one.
And Gabe on Kuwait aligned perfectly with our existing therapeutic focus areas in neurology and endocrinology. So the cost to commercialize will naturally be lower and synergistic with our flexible on.
So these are the Firefly it'd be two program. So they naturally require lower development cost and carry lower approval rate versus novel molecule development. Our passion is patient centric and we believe these technologies have the potential to meaningfully improve existing products and improve quality of life.
Four patients falling day expected close on what acquisition, Okay, SP will be positioned to launch at least one specialty product per year starting in 2023.
Across our company, we are pleased with our 'twenty 'twenty performance and results. Our collective efforts have also sparked remarkable momentum for continued growth in 'twenty 'twenty, one and for years to come together, we remain motivated and driven by a single purpose to make healthy.
Possibly but I will turn the call over now to pass those.
Thank you Tim let me start with our fourth quarter financials, and then move to the full year 2020, and finally discuss on 2021 guidance net.
Net revenue for the fourth quarter was $510 million up 100, net $13 million or 28% compared to Q4 2019.
Care accounted for $82 million, while the combined generics and specialty business grew 31 million or eight per cent.
Generics net revenue of $342 million was up 42 million or 14% compared to Q4 2019 majority of growth was driven by products launched in 2020, as well as tailoring and should crowd fate, while solid growth as the rest of our portfolio.
Offset declines in levels higher oxide and day clock Tonight.
Specialty net revenue of 85 million was down $12 million or 12% and essentially flat on a sequential basis.
This performance reflects three factors.
Consistent double digit growth of our promoted brands writer in unit volume.
Second a large non recurring return of a discontinued product from a single customer and finally, lower and burn due to COVID-19.
Adjusted gross margin of 46% was in line with our expectations.
Generics were at 38 per cent compared to 33% in Q4 of 2019.
While the adjusted gross margin per ask your specialty was 17% and 74% respectively consistent with their overall 2020 average performance.
Adjusted EBITDA of 107 million was up $27 million or 33% compared to Q4, 2019, reflecting strong generic growth and tight expense management.
Adjusted diluted EPS of 14 cents was well ahead of the eighth century reported in Q4 2019, mainly driven by the adjusted EBITDA growth and lower interest expense.
Let me now summarize our full year 2020 performance.
Total net revenue was almost $2 billion up $367 million or 23% versus 2019.
Generics were 1.345 billion up $34 million on 3%. This growth reflects the 2020 new product launches.
Moving into crowd paid offsetting levels tire oxide and diclofenac competition and broad market share gains offset the oxymorphone rig plus and COVID-19 headwinds we discussed in prior quarters.
Specialty 'twenty 'twenty net revenue was $356 million up $38 million or 12%.
Oxymorphone added $28 million, while double digit growth of Rytary unit, Troy offset declines in the non promoted brands.
As well as COVID-19 related disruptions.
Our current 2020 net revenue was $294 million driven by both the RMS distributions and government segments.
Adjusted gross margin for 2020 was 41, 6% in line with our expectations.
This reflects the 280 basis points expansion for generics to 38, 3%, mainly due to new product launches.
Specialty of 74.2% stable throughout 2020, and finally Oscar at 17, 5% in line with full year average.
Adjusted EBITDA for 2020 was 456 million up $181 million or 28% compared to 2019.
On a standalone basis, <unk> contributed $46 million.
Adjusted diluted EPS for 2020 was 63 well.
Well ahead of our 35 reported in 2019.
From a cash perspective, we generated a record level of operating cash flow of $379 million.
Excluding the $100 million tax refund will discuss in the second quarter, we delivered $269 million compared to $2 million in 2019.
This performance was ahead of our guidance range of $170 million to $220 million, partly due to favorable timing of collections and processing of expenses by key certain customers.
As a result of our strong performance and nobody is in a much stronger financial position today.
As a point of reference our cash on hand at December 2020 was $347 million compared to $153 million in December 2019.
And as I've mentioned, our net debt to adjusted EBITDA improved to five three ex compared to seven ex a year earlier and finally, we're generating substantial amounts.
Cash.
Let me now turn to our 2021 guidance, where we expect another year of growth.
First we expect net revenues in the range of two point in $1 billion to $2.2 billion scenario ex growth should accelerate from that 3% in 2020 as new product launches continue legacy issues are behind us and less COVID-19 related disruptions.
And specialty writer and unit rate growth will offset the exclusivity loss of Zomig as the business begins to ready itself for future new product launches.
Our care is expected to grow at double digits by leveraging long term contracts and less COVID-19 disruptions.
Second we expect adjusted EBITDA in the range of $500 million to $540 million.
Our growth expectations, our balance and include full year benefits of product launches already taken place.
<unk> 2021, Atlantis and operating expense efficiency actions.
Our guidance also includes investments in R&D to drive long term volume.
Higher SG&A to increase our commercial commercial footprint in neurology, and endocrinology and higher expenses in general as economic activity picks up throughout 2021.
Third we expect adjusted EPS in the range of 70 to 85.
At the current statutory federal tax rate, reflecting strong adjusted EBITDA flow.
Fourth we expect Capex in the range of $60 million to $70 million as we continued to invest in new technologies to support our strategy of expanding our complex new product offerings.
Finally, we expect operating cash flow in the range of $220 million to $250 million, which reflects the fourth quarter 2020 timing benefits I discussed earlier.
As you May have noticed we did not provide specific gross margin guidance. This.
This is due to the fact that our three segments give such diverse profiles, but the shift in the mix of business can give us substantially.
Nevertheless, we expect gross margin expansion in 2021 that will be led by our generic business and we also expect stability with specialty and other care with.
With that let me turn it over to Sheila. Thank you doses. We're pleased with the strong performance delivered over the last year and are confident.
We are well positioned to drive growth in 2021 and beyond with a revenue of two point of our strategy.
I would now like to turn the call over to the operator to take your questions. Thank you.
We will now begin the question and answer session to ask a question you May Press Star then one on your telephone keypad. If you are using a speakerphone. Please pick up your handset before pressing the keys if at any time. Your question has been addressed and you would like to withdraw.
Your question. Please press Star then two.
At this time, we will pause momentarily to assemble our roster.
The first question.
From David M Selim Piper Sandler.
Please go ahead.
Hey, Thanks, just a couple so wanted to first.
Get some additional color on.
The top line.
Guidance and particularly on can you talk about how.
You're thinking about approval and contribution from complex.
Generics, obviously you had the news today.
On the patch. So so that's in there, but what else is on is baked in to the top line.
EBITDA I mean do you have a risk adjusted contribution from say, a copaxone generic which you talked about on the past or doors. All so just help us understand what's in there.
Then secondly on on the Biosimilars I know you talked about the three the Pegfilgrastim Filgrastim and Bevacizumab.
But are you prepared to talk about additional products.
Products that you're investing in and.
And just to talk about.
What we might see in the.
Coming year.
In terms of additional opportunities. Thanks.
Well. Thank you Eric let me start plus and then I'll turn it over to <unk> for more details.
So your first question is on Npls as you know genetics.
Npls, we do not list them out water compared to duties.
Our track record speaks for itself, we deliver best this time to give you more color.
Slide number eight and nine of the presentation. So if you look at those gives you the pending pipelines on each major categories, where we have been very successful, which now includes nine categories. So if you go to slide eight you on in suits and plans.
During vaginal ring all those we introduced on the talk already.
The volume it tells you what's in the pipeline.
Patches, we have gotten pretty much five bags is approved and it was a remarkable achievement to get the.
Does that for me.
This ruling patch on route.
It comes from our new like New England, New Jersey.
Facility so.
So we are in the pipeline day topical is we still have good products.
Oral liquids and topic loans nasal spray, we still having all these impressive choose on in.
New Jersey manufacturing sites.
The injectables, so now that the big growth area as well this year, we will launch for you, but in coming years as Jim mentioned, we got multiple products a sub sector of Gx, which we would say injectables. We had only last year, we did $112 million.
We have a huge growth potential in coming years, including we just invested in the large volume guidance rolled products as well and other sterile products like Apollo makes.
Coming as well, we expect that to close launch Alcoa inhalation products from our Irish plant and we haven't typically few OSB products and page nine shows you what spending at FDA and we further broke down which we consider the exclusive <unk> single source.
High value launch on approval and then bunch of paragraph four.
So it's a very nicely architected pipeline to do six seven.
High value launches every year, we still expect on other six seven this year.
And next year to even more.
What I do product the pipeline of 93 products.
Only 80% or.
80 per cent products are non oral solids. So hopefully that answers. Your question I did not give you specific products, where I gave you enough to give you the color on our new product launches I'll answer the Biosimilar question, plus and then passes can add a bit more so and it's a broad question.
And I know.
I'll get this question repeatedly the award is a strategy so as we have.
Build ourself as the affordable Medicine company over the years.
We look at Biosimilars as part of that.
So with Engie ex we have nine categories.
We started in 2012 13 investing in the complex generics products and all of the platforms. They are all in house.
Biosimilars.
We're doing the same.
We start with starting out slow.
Believe it's more of a complex generics market. It will behave like that the players will have lot of say on it based on this day hospital based products you got to deal with.
Good day.
The the buy and Bill model.
You would have to deal with the clinics. So eventually based on which bear influence. If you will have it will become more complex generics, we all know that it will have.
Competition.
Sometimes three sometimes 456. Unlike complex generics. If you are third fourth fifth you will have them.
Much lower market share than the flow stream. So our goal going forward. After these three products.
Cost efficient way the all of the products, we've been working with FDA on.
On it.
So less ultra clinical trials have commercial strategies, which doesn't break our bank.
Because it's competitive marketplace.
And the next.
Just slightly rebuild the complex genetics. The next set of Biosimilars and we're here to play in this for 10 years. So we don't even look at quarter or one year.
We will build this and we will be the leading players in coming years. So we are more focusing on how can be close to a second on the next by the next day or I'll call. It on Biosimilars and eventually we are looking at building.
Manufacturing facility in the United States, because actuaries do a key advantages with a high quality manufacturer and it will matter a whole lot as we progress through the Biosimilars as you know market is really good over the next 10 15 years.
<unk> you want to add.
No. This was great Hey, David good morning.
Good morning, a couple of thoughts we feel great about the topline.
Number one so let's talk a little bit about generics, which is a little bit like running on a treadmill right because all of US know the continued price pressures. However, I came over the last 18 months and his team has done a great job gaining market share and leveraging their commercial skills and leveraging.
The strong pipeline we have built.
So as a result, we are not just simply looking to replenish revenue on solidly rely on new product introductions.
The base business, that's going to do very well very high on resiliency number one.
Number two in the latter part of your show B.
Generics growth rate in Q4, it was up 14%. So a big part of it is the benefit of the new product introductions that have already taken place already taken place in the second half of last year and now those are feeding are feeding into that.
The topline revenue strength and then number three we continue to innovate brighter tend to have a huge team of 900 scientists have not stopped generating new andas and getting approvals dual lane was it was a great success. This morning.
So the 2021.
New product launches will continue to drive growth in the generic space, which is why we expect growth rate in generics to accelerate from the 3% of this year.
That's point number one.
Point number two odd care has done a great job growing at double digit growth rates on the top line, we talked about the EBITDA on the bottom line is not as high but a lot of it was just kind of Covid COVID-19 implications. So we expect another double digit growth for other carrier in 2021.
And finally, our specialty business.
Our specialty business is in a bit of a transition right.
Rytary units are going to grow double digits. The same way. They grew in 2020, and we're also making investments in that space in terms of expanding our field force and our commercial footprint as I mentioned.
At the same time zone.
On a go off patent we have a thoughtful strategy.
In terms of sharing the majority of the generic market share. So that's going to offset some of the headwinds.
But at the same time the business is going to grow it's not going to grow at 12% growth in 2020, which is why it but it's going to grow and it's also in transition.
As the team is getting ready for new product launches such as IP extraordinary K 127 over the next couple of other next few years.
And then finally right you know we expect I know some folks are wondering hey, how do you think about the COVID-19 assumption listen last year within in the thick of things and we ended up increasing both topline and bottom line guidance. Our expectation. This year is COVID-19 issue will persist.
Right right.
We're not anticipating magically going away at the same time, though we expect less of an impact.
If you remember last year in Q2, and Q3 alone I spoke about $30 million of topline order, who cannot fulfill because of the strategy.
The supply chain.
<unk> tend to interest team who've done a great job rebuilding our pipeline. So we're expecting headwinds not quite as much as 2020, so little lengthy but hopefully that addressed your question.
Helpful. Thanks, guys.
The next question comes from Gary Nachman of BMO capital markets. Please go ahead.
Yeah.
Hi, good morning.
First Kashi, there's a very good source of pipeline for you are there are a lot of other small companies you've identified to potentially do deals with them as you look to expand in specialty would that just be in the current areas neurology and endocrinology or would you consider going beyond that.
And then ex U S.
Aside from extending in China, which you highlighted.
Where else would you go in terms of other regions and just talk about the pace of that expansion, how aggressive you're going to be to diversify the business geographically. Thank you.
Thank you Gary.
So PSP.
Excellent pipeline in the drug delivery platform, which allows us to.
Growing our current <unk>, which is neurology and endocrinology.
We are.
Targeting the products.
And then the older molecules, where we can use our drug delivery technologies.
In Peru, lastly, the Olin might needs over 30 years 20 years ignored by Big pharma.
Because these are not big revenue products, it would become somewhere between $100 million to $300 million. So we could look into other specialty.
<unk> declined more opportunities to address the annuity technologies, but right now we're solely focused on neurology and endocrinology and we would add commercial assets as well as pipeline assets. We are we want to make some I shouldn't be a much larger portion of our news business going forward and as we.
Launching these products on a U N on specialty we would be.
Out licensing it globally ex U S.
Specialty product as well.
The second question on China, China is very attractive because as you know force soon as the west did interest in our new Cigna.
Significant position equity position and that means we have trusted partner in China and in top three in China.
Which allows us to.
Worked on it over two years now since we came back.
<unk> acquired a great pipeline.
I'm pleased to see the forecast currently on China. So in 2023, it looks better than the United States with certain genetics molecule.
We expect to have a meaningful presence in China and continue on to building.
Partnership and.
Portfolio, the second market, we naturally euro and it'll be just Florida with high value products within our pipeline like inhalation certain injectable products technology driven products. So we're not looking too.
To have hundreds of andas out in international.
International markets weighted targeted.
As you know it's crowded so we just wanted to take on best assets and increase it would be additional revenue to our U S based revenues.
Thank you.
Okay. There was one other just on Kashi are there a lot of other deals like that that you've identified.
Sure.
Right now we are more on the focus on the commercial so we have we have a good targets on commercial and we are actively pursuing then we will look into pipeline and that sort of passions.
Yeah.
It's both the R&D income ratio, but right now commercial for a few quarters.
Okay got it thank you.
The next question comes from Elliot Wilbur of Raymond James. Please go ahead.
Thanks, and good morning, congratulations on the Oh whatsoever on <unk> approval I'll make sure I am pronouncing it right is it is it that for me I'm curious as to what your capacity is to supply that market. What do you think you can obtain in terms of market share and also interestingly, it's been a market that's been.
Rowing at 15% to 20%.
Year on year and I'm wondering if you think there's potential for that to actually accelerate now what they a second debt.
Product in the market and I just wanted to follow up I know you've kept me going through quite a bit of detail in terms of potential launch cadence and some of the constitution of the products over the balance of the year, but previously you said you were cautiously optimistic you'd see a generic copaxone in the second half of 'twenty 'twenty, one and also a respiratory product.
I'm wondering if that's still the case and then just a quick follow up question for Josh on the gross margin dynamics in the generic business I know that you've been kind of working towards that 30, or 40%, mark and and aren't quite there yet but in thinking about debt number going forward.
Are we at a point, where new product dynamics are really distorted the driver.
Incremental improvement in that metric and how can we think about that number longer term is still seems like there's a lot of room for upward.
Movement.
In gross margin metrics, but I'm not sure ultimately at this you think this business can be a 45 per cent margin business or maybe even something better if we think out three to five years. Thanks.
Thank you Elliot.
So your first question on the Zephyr need also abra.
Our manufacturing capabilities as you know, we always say that all of these complex manufacturing, we do not build out 100% capacity.
Capex will not justify as we always expect competition to come in so in this case, we are starting out at around 35% going to 50 per cent in few months. So it's a good capacity and that's how we have allocated over to Capex, there and we as we have always seen when we launch.
Sucralfate category market grew so we expect the market to grow in genetics options that are available.
Second question on Copaxone and respiratory products, we are optimistic this year to be launched both.
And your third question I, just wanted to historically point out that we because of low to accretion CES and the new product launches, we always enjoying higher gross gross margin in most of the products, 90% plus we make by ourselves. So we do not share.
In a in profits with other.
Our partners. So we expect the gross margins to grow but taxes will give you more color.
Hey, Elliot good morning, So a couple of thoughts.
Generics gross margin listen I think the business did great. This year right. So we had for the year full year gross margin of about 38% 38, 3% actually.
Versus 35% last year. So there was almost 300 basis points improvement in one year.
And we're only just scratching the surface in terms of new product introductions.
And as you know new products for us here the substantially higher margin.
On the 38% right, which gives us the confidence to say that we continue to go after generic gross margin in excess of 40%.
Whether or not we will get to the excess of 40% plus in 2021, not quite sure but the trajectory is definitely positive number one and number two as you average it too.
Remind me the legacy M. Your gross margin was substantially index of 40%. So long term, we're chasing excess of 40% on whether or not this 45 or so.
That's probably.
A good a good target over time.
That's number one number two is one of the key drivers of gross margin improvement is actually twofold number one is new product introductions as I mentioned before they have a an average gross margin substantially more than 70 per cent well I'm, sorry substantially more than the 40% number one but also very substantial.
Mount of cost efficiency should continue to go after or the cost of goods line is about $1 billion right. So we're actively looking for efficiencies whether or not is pushing our purchasing teams to improve our purchasing power whether or not is bringing in house right might.
Manufacturing of products manufactured by third party. So I think that continues to represent a good opportunity for us over time.
And then and then finally as you know of care of gross margins I still believe there is room for improvement there and then specialty and I think we're looking for stability for next year and over time right as a new pipeline plays out I think we're looking to expand those margins as well.
Worked for you on here.
Yeah, that's perfect. Thank you.
The next question comes from Amit Bhatia of SVP Leerink. Please go ahead.
Hi, This is Lee on for Ami, Thanks for taking the questions maybe.
Two if I counted on.
Just on Nuvaring curious, how you're thinking about the durability of this product in 2021 given.
There is additional generic entrants.
And then carafate.
Expect to other generic this year and then maybe just.
Yeah more bigger picture you know we're in the early days of the New U S Presidential administration.
Curious if there's been any updated views or discussions around initiatives on domestic manufacturing firsthand on medicines are you guys could participate in this thank you.
Well, thank you very much on new ordering.
Teva launched the product. So we already have a competition, we may get another competitor as well.
Mind, you we are on market share was at <unk>.
20% now we grew two <unk> since the volume is offsetting the pricing pressure and we still see as in durables.
Good product it's complex. So this year contribution is great and going forward on.
Forward it could be a good contribution.
As always complex smart exploit.
Great. We haven't heard any income competitors. If it comes through it's a large market and it will be a meaningful contributor this year.
And your question on the.
Martina administration. They already gave you the 100 days review pro forma share legal manufacturing supply chain.
Specifically focusing on <unk>.
Essential Madison and what we make in America, and what we don't and the 100 days review will reveal that we don't make much here due to the competitive pressure everybody has a knee and especially last 40 years more magnified remember in 2016 17 vs Tortola.
Moving to see used to make $60 million.
Unit dose and the oral solids in the United States with some 100 plus facility add back that number is much lower I would say less than probably $20 billion in the United States. So that's just one example of biologics we don't make much share there as well so we need to have 35% 40% of.
Capacity and capabilities to in case of any emergencies, whether it's by NAV made where there's I'm not against the global supply chain that is moving to happen. It is needed we buy ourselves out of a global supply chain, but why not have at least 35% to 40% capabilities and capacity.
Right here in our own country and that sort of Bard and administration is.
Reviewing also the Congress is utmost interest at both sides awhile to making this happen and the states.
Many states are stepping up to have manufacturing and.
High end capabilities and universities are supporting the initiatives and why not guidance as simple as generics biosimilars products light node, we make them in the United States.
Great. Thank you.
The next question comes from Gregg Gilbert of Truest. Please go ahead.
Hi, Good morning can you walk person enrollment update for two or three and when you expect when do you expect to file the NDA.
I have a question on generic visa strict I'm curious, if immunogenicity or other technical questions might make that a difficult approval to to get soon I assume it's a when not an if but maybe you could.
Sure your thoughts on the profitability and the hurdles there and lastly on NAV character I'd you talked about how that's going how does that play into your strategy longer term should we think about it is just something that kind of chugs along assets going in and participates in growth of the industry or does it play a bigger role in your longer term strategy and our.
Are there other ways to leverage it thank you.
Thank you Eric go ahead, Joe sure I'll just touch on on.
That takes two or three Greg we're not going to comment on a specific patient numbers, but we are on track to have topline results.
By the fourth quarter of this year there is a safety follow up and we do expect to be in position to file the NDA by the middle of 'twenty two.
Yep.
And do you underwrite anything.
Generic low.
But two filing turned into a non resin price thing or you are waiting for the FDA comments.
We haven't heard anything on immunogenicity or any other roadblocks, but.
We have a in depth understanding of the peptides than other biosimilars and our.
Are there areas of expertise in house so.
Didn't really create a great.
To swiftly on certain see a response that comes from after the year.
And on a biosimilar.
This is a brought on player for us long term and will be focused on science and manufacturing capability.
All further into bio stimulant and.
Uh huh.
Doug mentioned, we will focus on first or second.
Our company to come out in the second we were Biosimilar and it was low.
Long haul for next five to 10 years, but these markets are most market.
And Gregg on your question Forever can say okay.
Bart.
<unk> brought them as part of a meal is because of two main reasons one is the.
The set business with <unk>.
We like that segment.
There are multiple products coming off I didn't flow.
So we expect that to grow and second as unit dose business.
Is.
It's a nascent stages.
Launching eight plus.
Unit dose and liquid from a branch with New Jersey facility.
So that that should grow on a unit dose and the third one is how do we get closer to one step closer to customers. So we may use of cash platform, which we are not ready to talk about it.
On how it will play, but we're always looking to get one step closer to customers.
Okay. Thank you.
Thanks.
The next question comes from Biology Prasad of Barclays. Please go ahead.
Hi, good morning, everyone. Thanks for the questions.
A lot of them have been answered just on.
I'll tell you about it.
So I saw that you have of CGT designation, giving you want 80 days exclusivity, but seen that Mylan has been alone in this market for the past six years its fair to assume that there is no other competitor on day 181 hour anytime in the near future.
That is one.
Two on Biosimilars and again a lot of collection.
Also one of your peers.
On the Biosimilar side recently signaled a strategically what's shown on this segment.
And what does this imply for you in terms of the opportunities how does it influence future thoughts around investments into the space that.
That would be helpful. Thanks.
And thank you biology, so also over the competition would be very limited if any this year.
And we'll leave it there where now it's extremely complicated complex product on Biosimilars. The competitors right. It is you can't invest $150 million where product.
Return will not be debt.
It has to be this strategy that we every day, it's cost depletion development and cost efficient commercialization.
What is the meaning having 150 200 people to.
<unk> sales force the same product Biosimilar those genetics products. So we believe it's just going to play more like complex generics in coming years and the players that company that.
Invest in manufacturing in science is integrated not sharing to margins high.
High quality manufacturing will matter a whole lot here and I believe domestic manufacturing will make a big case as well and you have the guardian portfolio.
510, 15, 20 products and those other companies.
It's right in what we do.
It's in our nations.
On a as the affordable Medicine company, leading in the United States.
Thanks, guys. How are you going to play out thank you balance.
Just one follow up maybe on that if the cost of investments are significantly lower and should be low or do you anticipate more competition on more companies exploring our entering the field, let's say two three years from now.
I think if all of your balance sheet similar to complex generics like caster molds and it's more complex. Even then all of these these micro square Injectables and is in fact.
Non peptide the biologics manufacturing is not an easy task. It's a lot is in one day.
So yes, there will be competition, but we can.
Consistently supply is going to be the key high quality product.
Yes.
And due to time constraints. The last question questioner will be Dana Flanders with Guggenheim. Please go ahead.
Okay.
Great. Thank you for squeezing me in I just had two quick ones, maybe just first on the generics.
<unk> base business, just wondering if you could comment.
How you see it positioned from a diversification standpoint, I know there are always upside and downside risk to guidance, but to me at least it seems like just from a revenue and gross profit perspective.
Just much better diversified than a few years ago.
And then just my second quick question on R&D spend just as you increase investment and focus on the branded business.
What does that mean for total R&D spend over time should we think of some upside bias.
To that number or do you share some value from kind of lower you know what.
Shifts on some spend from lower value generics over to brands. Thank you.
Thank you Dana and good to hear from you. The first one is at the generic business Youre right. The few years ago. We were highly concentrated on a few products. Since we have launched mainly complex products now it is highly diversified and the key thing is we will keep launching six seven more complex products every year.
<unk> the pipeline and also finding opportunities within based business as we have a more on capacity for transdermal topical liquid injectables. So is all of the Subsectors of Gx, we're expanding to offset the continuous pressure, which is lower than previous year.
On a base business.
On R&D as you know is this final required me to other than these and we will be allocating more and more dollars to specialty then then genetics, but we will stay at around 161 74 now as we grow.
We will invest.
Smartly in more but again, it's Wi Fi me too so theyre non AMC kind of expenses.
So I hope that answers your question.
Great. Thank you.
Thanks.
This concludes our question and answer session and the Ann Neale Pharmaceuticals fourth quarter and full year 2020 earnings call. Thank you for attending today's presentation. You may now disconnect.
Okay.
[music].